Condition: Congestive Heart Failure · Heart Failure, Systolic · Heart Failure · Sponsor: Sardocor Corp.
It is believed that targeted SERCA2a enzyme replacement in HFrEF patients will correct defective intracellular Ca2+ hemostasis, resulting in improved cardiac contractile function and energetics which will, in turn, translate to improved clinical outcomes. Additionally, it is hypothesized that correcting SERCA2a dysfunction will also improve coronary blood flow through correction of the impaired endothelium-dependent nitric oxide-mediated vasodilatation observed in heart failure.
This description comes directly from the study's public registry record.
COO · 858-752-2941 · info@sardocorcorp.com
Always discuss trial participation with your own doctor first.
| San Diego Cardiac Center | San Diego, California, United States | Recruiting |
| University of California, San Francisco | San Francisco, California, United States | Recruiting |
| Washington University in Saint Louis | St Louis, Missouri, United States | Recruiting |
| University of Texas Southwestern Medical Center | Dallas, Texas, United States | Recruiting |
| University of Washington Medicine | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04703842